Metabolomics and the diagnosis of human diseases -A guide to the markers and pathophysiological pathways affected

Current Medicinal Chemistry

Volumn 21, Issue 7, 2014, Pages 823-848

  Medina, S ^a   Dominguez Perles R ^a   Gil, J I ^b   Ferreres, F ^a   Gil Izquierdo, A ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Bone; Cancer; Cardiovascular disease; Celiac disease; Crohn's disease; Depression; Diabetes; Inborn errors of metabolism; Metabolomics; Neurological disease

Indexed keywords

ACUTE CORONARY SYNDROME; ALZHEIMER DISEASE; ARGININOSUCCINIC ACIDURIA; ARTICLE; ATHEROSCLEROSIS; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASES; DOWN REGULATION; ESOPHAGUS CANCER; FECES ANALYSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOMOCYSTINURIA; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; IDIOPATHIC INTRACRANIAL HYPERTENSION; INBORN ERROR OF METABOLISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INTERSTITIAL CYSTITIS; KIDNEY CARCINOMA; LESCH NYHAN SYNDROME; LIVER CELL CARCINOMA; LUNG CANCER; MAPLE SYRUP URINE DISEASE; METABOLITE; METABOLOMICS; METHYLMALONIC ACIDEMIA; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OVARY CARCINOMA; PANCREAS CANCER; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENYLKETONURIA; PREECLAMPSIA; PROPIONIC ACIDEMIA; PROSTATE CANCER; REPERFUSION INJURY; SALIVA ANALYSIS; SPUTUM ANALYSIS; STOMACH CANCER; TYROSINEMIA; ULCERATIVE COLITIS; UPREGULATION; UREMIA; URINALYSIS; UROGENITAL TRACT CANCER; UTERINE CERVIX CARCINOMA; BRAIN CANCER; CANCER DIAGNOSIS; CARDIA; CENTRAL NERVOUS SYSTEM CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; EPITHELIAL OVARIAN CARCINOMA; GENERAL ASPECTS OF DISEASE; HERITABLE CORONARY ARTERY DISEASE; PLANNED MYOCARDIAL INFARCTION; REVIEW; WORKFLOW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISCRIMINANT ANALYSIS; HUMANS; METABOLISM, INBORN ERRORS; METABOLOMICS; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 84893589687     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867320666131119124056     Document Type: Article

References (144)

1. García-Cañas, V.; Simó, C.; León, C.; Cifuentes, A. Advances in nutrigenomics research: Novel and future analytical approaches to investigate the biological activity of natural compounds and food functions. J. Pharmaceut. Biomedic. Anal., 2010, 51, 290-304.
2. Ovesná, J.; Slab, O.; Toussaint, O.; Kodí-ek, M.; Marík, P.; Pouchová, V.; Vank, T. High throughput 'omics' approaches to assess the effects of phytochemicals in human health studies. Brit. J. Nutr., 2008, 99(E-SUPPL. 1), ES127-ES134.
3. Wishart, D. S. Metabolomics: Applications to food science and nutrition research. Trends Food Sci. Technol., 2008, 19, 482-493.
4. Zhang, X.; Yap, Y.; Wei, D.; Chen, G.; Chen, F. Novel omics technologies in nutrition research. Biotechnol. Adv., 2008, 26, 169-176.
5. Orei, M.; Simell, S.; Sysi-Aho, M.; Näntö-Salonen, K.; Seppänen-Laakso, T.; Parikka, V.; Katajamaa, M.; Hekkala, A.; Mattila, I.; Keskinen, P.; Yetukuri, L.; Reinikainen, A.; Lähde, J.; Suortti, T.; Hakalax, J.; Simell, T.; Hyöty, H.; Veijola, R.; Ilonen, J., Lahesmaa, R.; Knip, M.;Simell, O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J. Exp. Med., 2008, 205, 2975-2984.
6. Barnes, S. Nutritional Genomics, Polyphenols, Diets, and Their Impact on Dietetics. J. Am. Diet. Assoc., 2008, 108, 1888-1895.
7. Rezzi, S.; Ramadan, Z.; Fay, L. B.; Kochhar; S. Nutritional metabonomics: Applications and perspectives. J. Proteome Res., 2007, 6, 513-525.
8. Rimbach, G.; Boesch-Saadatmandi, C.; Frank, J.; Fuchs, D.; Wenzel, U.; Daniel, H.; Hall, W. L.; Weinberg, P. D. Dietary isoflavones in the prevention of cardiovascular disease -A molecular perspective. Food Chem. Toxicol., 2008, 46, 1308-1319.
9. Goonerwardena, S.N.; Prevette, L.E.; Desai, A.A. Metabolomics and atherosclerosis. Curr. Atheroscler. Rep., 2010, 12(4), 267-272.
10. Mamas, M.; Dunn, W.B.; Neyses, L.; Goodacre, R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch. Toxicol., 2011, 85, 5-17.
11. Koulman, A.; Volmer, D. A. Perspectives for metabolomics in human nutrition: An overview. Nutr. Bull., 2008, 33, 324-330.
12. Madsen, R.; Lundstedt, T.; Trygg, J. Chemometrics in metabolomics-A review in human disease diagnosis. Analytica Chim. Acta, 2010, 659, 23-33.
13. Kim, K.; Aronov, P.; Zakharkin, S.O.; Anderson, D.; Perroud, B.; Thompson, I.M.; Weiss, R.H. Urine metabomolomics analysis for kidney cancer detection and biomarker discovery. Molec. Cell. Proteomics, 2009, 8, 558-570.
14. Kim, K.K.; Taylor, S.L.; Ganti, S., Guo, L.; Osier, M.V.; Weiss, R.H. Urine metabolimic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS A J. Integrative Biol., 2011, 15, 1-11.
15. Saude, E.J.; Adamko, D.; Rowe, B.H.; Marrie, T.; Sykes, B.D. Variation of m etabolites in normal human urine. Metabolomics, 2007, 3, 439-451.
16. Saude, E.J.; Sykes, B.D. Urine stability of metabolomic studies: effect of preparation and storage. Metabolomics, 2007, 3, 19-27.
17. Yan, S.K.; Wei, B.-J.; Lin, Z.Y.; Yang, Y.; Zhou, Z.T.; Zhang, W.D. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncology, 2008, 44, 477-483.
18. Sugimoto, M.; Wong, D.T.; Hirayama,k A.; Soga, T.; Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics, 2010, 6, 78-95.
19. Davis, V.W.; Bathe, O.F.; Schiller, D.E.; Slupsky, C.M.; Sawyer, M.B. Metabolomics and surgical oncology: potential role for small molecule biomarkers. J. Surg. Oncol., 2011, 103, 451-459.
20. Erb, G.; Elbayed, K.; Piotto, M.; Raya, J.; Neuville, A.; Mohr, M.; Maitrot, D.; Kehrli, P.; Namer, I.J. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magnetic Resonance Med., 2008, 59, 959-965.
21. Monleón, D.; Morales, J.M.; Gonzalez-Darder, J.; Talamantes, F.; Cortés, O.; Gil-Benso, R.; López-Ginés, C.; Cerdá-Nicolás, M.; Celda, B. Benign and atypical meningioma metabolic signatures by high-resolution magic-angel spinning molecular profiling. J. Proteome Res., 2008, 7, 2882-2888.
22. Lyng, H.; Sitter, B.; Bather, T.F.; Jensen, L.R.; Sundfør, K.; Kristensen, G.B.; Gribbestad, I.S. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer, 2007, 7, 11.
23. Moestue, S.; Sitter, B.; Bather, T.F.; Tessem, M.B.; Gribbestad, I.S. HR MAS MR Spectroscopy in metabolic characterization of cancer. Curr. Topics Medic. Chem., 2011, 11, 2-26.
24. Zhou, J.; Xu, B.; Huang, J.; Jia, X.; Xue, J.; Shi, X.; Xiao, L.; Li, W. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clinica Chim. Acta, 2009, 401, 8-13.
25. Xie, G.X.; Chen, T.L.; Qiu, Y.P.; Shi, P.; Zheng, X.J.; Su, M.M.; Zhao, A.H.; Zhou, Z.T.; Jia, W. Urine metabolite profiling offers potential early diagnosis of oral cancer. Metabolomics, 2011, 8(2), 220-231.
26. Kim, Y.; Koo, I.; Jung, B. H.; Chung, B. C.; Lee, D. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics, 2010, 11(SUPPL. 2), S4.
27. Woo, H. M.; Kim, K. M.; Choi, M. H.; Jung, B. H.; Lee, J.; Kong, G.; Nam, S. J.; Kim, S.; Bai, S. W.; Chung, B. C. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clinica Chim. Acta, 2009, 400, 63-69.
28. Slupsky, C.M.; Steed, H.; Wells, T.H.; Dabbs, K.; Schepansky, A.; Capstick, V.; Faught, W.; Sawyer MB. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res., 2010, 16, 5835-5841.
29. Asiago, V.M.; Alvarado, L.Z.; Shanaiah, N.; Nagana Gowda, G.A.; Owusu-Sarfo, K.; Ballas, R.A.; Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res., 2010, 70, 8309-8318.
30. Mountford, C.E.; Somorjai, R.L.; Malycha, P.; Gluch, L.; Lean, C.; Russell, P.; Barraclough, B.; Gillett, D.; Himmelreich, U.; Dolenko, B.; Nikulin, A.E.; Smith, I.C. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Brit. J. Surg., 2001, 88, 1234-1240.
31. Budczies, J.; Denkert, C.; Müller, B.M.; Brockmöller, S.F.; Klausche, F.; Györffy, B.; Dietel, M.; Richter-Ehrenstein, C.; Marten, U.; Salek, RM.; Griffin, J.L.; Hilvo, M.; Ore-i M; Wohlgemuth, G.; Fiehn, O. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - A GCTOFMS based metabolomics estudy -. BMC Genomics, 2012, 13, 334-344.
32. Howell, A. Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. BMC Medicine, 2010, 8, 73.
33. Saldova, R.; Arnold, J.N.; Rudd, P.M. Glycobiomarkers and new technologies for the detection of lung cancer. Clin. Lab. Int., 2011, 35, 20-23.
34. Phillips, M.; Altorki, N.; Austin, J.H.M.; Cameron, R.B.; Cataneo, R.N.; Greenberg, J.; Kloss, R.; Maxfield, R.A.; Munawar, M.I.; Pass, H.I.; Rashid, A.; Rom, W.N.; Schmitt, P. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers, 2007, 3, 95-109.
35. Poli, D.; Carbognani, P.; corradi, M.; Goldoni, M.; Acampa, O.; Balbi, B.; Bianchi, L.; Rusca, M.; Mutti, A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respiratory Res., 2005, 6, 71.
36. Phillips, M.; Gleeson, K.; Hughes, J.M.B.; Greenberg, J.; Cataneo, R.N; Baker, L.; McVay, W.P. Volatile organic compounds in breath as markers of lung cancer: A cross-sectional study. Lancet, 1999, 353, 1930-1933.
37. Yang, Q.; Shi, X.; Wang, Y.; Wang, W.; He, H.; Lu, X.; Xu, G. Urinary metabolomics study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J. Sep. Sci., 2010, 33, 1495-1503.
38. An, Z.; Chen, Y.; Zhang, R.; Song, Y.; Sun, J.; He, J.; Bai, J.; Dong, L.; Zhan, Q.; Abliz, Z. Integrated ionization approach for RRLC-MS/MS-based metabolomics: Finding potential biomarkers for lung cancer. J. Proteome Res., 2010, 9, 4071-4081.
39. Isono, K.; Ochiai, T.; Okuyama, K.; Onoda, S. The treatment of lymph Node metastasis esophageal cancer by extensive lymphadenectomy. Japan J. Surg., 1990, 20; 151-157.
40. Zhang, J.; Liu, L.; Wei, S.; Gowda, N.; Hammoud, Z.; Kesler, KA.; Raftery, D. Metabolomics study of esophageal adenocarcinoma. J. Thoracic, Cardiovasc. Surg., 2011, 141(2), 469-475.
41. Cai, Z.; Zhao, J.S.; Li, J.J.; Peng, D.N.; Wang, X.Y.; Chen, T.L.; Qiu, Y.P.; Chen, P.P.; Li, W.J.; Xu, L.Y.; Li, E.M.; Tam, J.P.; Qi, R.Z.; Jia, W.; Xie, D. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Molec. Cell. Proteomics, 2010, 9, 2617-2628.
42. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
43. Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Saito, N.; Ochiai, A.; Tomita, M.; Esumi, H.; Soga, T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis. Time-of-flight mass spectrometry. Cancer Res., 2009, 69, 4918-4925.
44. Ikeda, A.; Nishiumi, S.; Sinohara, M.; Yoshie, T.; Hatano, N.; Okuno, T.; Bamba, T.; Fukusaki, E.; Takenawa, T.; Azuma, T.; Yoshida, M. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed. Chromatog., 2012, 26, 548-558.
45. Yang, J.; Xu, G.; Zheng, Y.; Kong, H.; Pang, T.; Lv, S.; Yang, Q. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J. Chromatog. B, 2004, 813, 59-65.
46. Bathe, O.F.; Shaykhutdinov, R.; Kopciuk, K.; Weljie, A.M.; Mckay, A.; Sutherland, F.R.; Dixon, E.; Dunse, N.; Sotiropoulos, D.; Vogel, H.J. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol. Biomarkers Prevention, 2011, 20, 140-147.
47. Patterson, A.D.; Maurhofer, O.; Benyo-lu, D.; Lanz, C.; Krausz, K.W.; Pabst, T.; Gonzalez, F.J.; Dufour, J.F.; Idle, J.R. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res., 2011, 71, 659-6600.
48. Wang, B.; Chen, D.; Chen, Y.; Hu, Z.; Cao, M.; Xie, Q.; Chen, Y. Metabolomics profile discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J. Proteome Res., 2012, 11, 1217-1227.
49. Zhang, H.; Wang, Y.; Gu, X.; Zhou, J.; Yan, C. Metabolomic profiling of human plasma in pancreatic cancer using pressurized capillary electrochromatography. Electrophoresis, 2011, 32, 340-347.
50. Beger, R.D.; Schnackenberg, L.K.; Holland, R.D.; Li, D.; Dragan, Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics, 2006, 2, 125-134.
51. Nishiumi, S.; Shinohara, M.; Ikeda, A.; Yoshie, T.; Hatano, N.; Kakuyama, S.; Mizuno, S., Sanuki, T.; Kutsumi, H.; Fukusaki, E.; Azuma, T.; Takenawa, T.; Yoshida, M. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics, 2010, 6, 518-528.
52. Chan, E. C. Y.; Koh, P. K.; Mal, M.; Cheah, P. Y.; Eu, K. W.; Backshall, A.; Cavill, R.; Nicholson, J. K.; Keun, H. C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res., 2009, 8, 352-361.
53. Nambiar, P.R.; Gupta, R.R.; Misra, V. An Omics based survey of human colon cancer. Mutat. Res./fundamental Molec. Mechanisms Mutagen., 2010, 693, 3-18.
54. Denkert, C.; Budczies, J.; Weicher, W.; Wohlgemuth, G.; Scholz, M.; Kind, T.; Niesporek, S.; Noske, A.; Buckendahl, A.; Dietel, M.; Fiehn, O. Metabolite profiling of human colon carcinomaderegulation of TCA cycle and amino acid turnover. Molec. Cancer, 2008, 7, 72.
55. Ludwig, C.; Ward, D.G.; Martin, A.; Viant, MR.; Ismail, T.; Johnson, P.J.; Wakelam, M.J.; Günther, U.L. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magnetic Resonance Chem., 2009, 47, S68-S73.
56. Ritchie, S.A.; Ahiahonu, P.W.K.; Jayasinghe, D.; Heath, D.; Liu J.; Lu, Y.; Jin, W.; Kavianpour, A.; Yamazaki, Y.; Khan, A.M.; Hossain, M.; Su-Myat, K.K.; Wood, P.L.; Krenitsky, K.; Takemasa, I.; Miyake, M.; Sekimoto, M.; Monden, M.; Matsubara, H.; Nomura, F.; Goodenowe, D.B. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Medicine, 2010, 8, 13.
57. Nishiumi, S.; Kobayashi, T.; Ikeda, A.; Yoshie, T.; Kibi, M.; Izumi, Y.; Okuno, T.; Hayashi, N.; Kawano, S.; Takenawa, T.; Azuma, T.; Yoshida, M. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One, 2012, 7(7), e40459.
58. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Liu, Y.; Xu, Y.; Ni, Y.; Zhao, A.; Cai, S.; Xu, LX.; Jia, W. Urinary metabonomic study on colorectal cáncer. J. Proteome Res., 2010, 9, 1627-1634.
59. Monléon, D.; Morales, J.M.; Barrasa, A.; López, J.A.; Vázquez, C., Celda, B. Metabolite profiling of fecal water extracts from huma colorectal cancer. NMR Biomed., 2008, 22, 342-348.
60. Ma, Y. L.; Qin, H. L.; Liu, W. J.; Peng, J. Y.; Huang, L.; Zhao, X. P.; Cheng, Y. Y. Ultra-high performance liquid chromatographymass spectrometry for the metabolomic analysis of urine in colorectal cancer. Digestive Diseases Sci., 2009, 54, 2655-2662.
61. Denkert, C.; Budczies, J.; Kind, T.; Weichert, W.; Tablack, P.; Sehouli, J.: Niesporek, S.; Ko-nsgen, D.; Dietel, M.; Fiehn, O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res., 2006, 66, 10795-10804.
62. Odunsi, K.; Wollman, R.M.; Ambrosone, C.B.; Hutson,A.; McCann, S.E.; Tammela, J.; Geisler, J.P.; Miller, G.; Sellers, T.; Cliby, W.; Qian, F.; Keitz, B.; Intengan, M.; Lele S.; Alderfer, J.L. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer, 2005, 113, 782-788.
63. García, E.; Andrews, C.; Huan, J.; Kim, H.L.; Sukumaran, D.K.; Szyperski, T.; Odunsi, K. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J. Proteome Res., 2011, 10, 1765-1771.
64. Buckendahl, A.C.; Budczies, J.; Fiehn, O.; Darb-Estafahani, S.; Kind, T.; Noske, A.; Weichert, W.; Sehouli, J.; Braicu, E.; Dietel, M.; Denkert, C. Prognostic impact of AMP-activated protein kinase expression in ovarina carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncology Rep., 2011, 25, 1005-1012.
65. Zhang, T.; Wu, X.; Ke, C.; Yin, M.; Li, Z.; Fan, L.; Zhang, W.; Zhang, H.; Zhao, F.; Zhou, X.; Lou, G.; Li, K. Identification of potential biomarkers of ovarian cancer by urinary metabolomics profiling. J. Proteome Res., 2012, 12, 505-512.
66. Chen, J.; Zhou, L.; Zhang, X.; Lu, X.; Cao, R.; Xu, C.; Xu, G. Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer. Electrophoresis, 2012, 33, 3361-3369.
67. Lokhov, P. G.; Dashtiev, M. I.; Bondartsov, L. V.; Lisitsa, A. V.; Moshkovskii, S. A.; Archakov; A. I. Metabolic fingerprinting of blood plasma from patients with prostate cancer. Biochemistry (Moscow) Supplement Series B: Biomed. Chem., 2010, 4, 37-41.
68. Sreekumar, A.; Poisson, L. M.; Rajendiran, T. M.; Khan, A. P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R. J.; Li, Y.; Nyati, M. K.; Ahsan, A.; Kalyana-Sundaram, S.; Han, B.; Cao, X.; Byun, J.; Omenn, G. S.; Ghosh, D.; Pennathur, S.; Alexander, D. C.; Berger, A.; Shuster, J. R.; Wei, J. T.; Varambally, S.; Beecher, C.; Chinnaiyan, A. M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.
69. Jentzmik, F.; Stephan, C.; Miller, K.; Schrader, M.; Erbersdobler, A.; Kristiansen, G.; Lein, M.; Jung, K. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol., 2010, 58, 12-18.
70. Jentzmik, F.; Stephan, C.; Lein, M.; Miller, K.; Kamlage, B.; Bethan, B.; Kristiansen, G,; Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J. Urol., 2011, 185, 706-711.
71. Cheng, L.L.; Burns, M.A.; Taylor, J.L.; He, W.; Halpern, E.F,; McDougal, WS.; Wu, C.L. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res., 2005, 65, 3030-3034.
72. Osl, M.; Dreiseitl, S.; Pfeifer, B.; Weinberger, K.; Klocker, H.; Bartsch, G,; Schäfer, G,; Tilg, B,; Graber, A,; Baumgartner, C. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics, 2008, 24, 2908-2914.
73. Thysell, E.; Surowiec, I.; Hombert, E.; Cmalic, S.; Widmark, A.; Johansson, A.I.; Stattin, P,; Bergh, A,; Moritz, T,; Antti, H,; Wikström, P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. Plos One, 2010, 5, e14175.
74. Szyma-ska, E.; Markuszewski, M.J.; Markuszewski, M.; & Kaliszan, R. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J. Pharm. Biomed. Anal., 2010, 53, 1305-1312.
75. Issaq, H.J.; Waybright, T.J.; Veenstra, T.D. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis, 2011, 32, 967-975.
76. Issaq, H.J.; Nativ, O.; Waybright, T.; Luke, B.; Veenstra, T.D.; Issaq,E.J,; Kravstov, A,; Mullerad, M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol., 2008, 179, 2422-2426.
77. Gao, H.; Dong, B.; Liu, X.; Xuan, H.; Huang, Y.; Lin, D. Metabonomic profiling of renal cell carcinoma: High-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate analysis. Anal. Chim. Acta, 2008, 624, 269-277.
78. Perroud, B.; Lee, J.; Valkova, N.; Dhirarpong, A.; Lin, PY,; Fiehn, O,; Kültz, D,; Weiss, RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer, 2006, 5, 64.
79. Catchpole, G.; Platzer, A.; Weiker, C.; Kempkensteffen, C.; Johannsen, M.; Krause, H,; Jung, K,; Miller, K,; Willmitzer, L,; Selbig,J,; Weikert S. Metabolic profiling reveals key metabolic features of renal cell carcinoma. J. Cel. Mol. Med., 2011, 15, 109-118.
80. Barderas, M.G.; Laborde, C.M.; Posada, M.; de la Cuesta, F.; Zubiri, I,; Vivanco, F,; Alvarez-Llamas; G. Metabolomic profiling for identification of novel potencial biomarkers in cardiovascular diseases. J. Biomed. Biotechnol., 2011. DOI: 10.1155/2011/790132.
81. Chen, X.; Liu, L.; Palacios, G.; Gao, J.; Zhang, N.,; Li, G.; Lu, J.; Song, T,; Zhang, Y,; Lv, H. Plasma metabolomics reveals biomarkers of the atherosclerosis. J. Sep. Sci., 2010, 33, 2776-2783.
82. Shah, S.H.; Bain, J.R.; Muehlbauer, M.J.; Stevens, RD,; Crossli,n DR,; Haynes, C,; Dungan, J,; Newby, LK,; Hauser, ER,; Ginsburg, GS,; Newgard, CB,; Kraus, W.E. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cariovasc. Genet., 2010, 3, 207-214.
83. Brindle, J.T.; Antti, H.; Holmes, E.; Tranter, G.; Nicholson, J.K.; Bethell, HW,; Clarke, S,; Schofield, PM,; McKilligin, E,; Mosedale, DE,; Grainger, DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1HNMR-based metabonomics. Nat. Med., 2002, 8, 1439-1444.
84. Teul, J.; Rupérez, F.J.; García, A.; Vaysse, J.; Balayssac, S.; Gilard, V.; Malet-Martino, M.; Martin-Ventura, J.L.; Blanco-Colio, L.M.; Tuñón, J.; Egido, J.; Barbas, C. Improving metabolite knowledge in stable aterosclerosis patients by association and correlation of GCMS and 1H NMR fingerprints. J. Proteome Res., 2009, 8, 5580-5589.
85. Shah, S.H.; Hauser, E.R.; Bain, J.R.; Muehlbauer, MJ,; Haynes, C,; Stevens, RD,; Wenner, BR,; Dowdy, ZE,; Granger, CB,; Ginsburg,GS,; Newgard, CB,; Kraus, WE. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol. Syst. Biol., 2009, 5, 258.
86. De Meyer, T.; Sinnaeve, D.; Van Gasse, B.; Tsiporkova, E.; Rietzschel, E.R.; De Buyzere, M.L.; Gillebert, T.C.; Bekaert, S.; Martins, J.C.; Van Criekinge, W. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal. Chem., 2008, 80, 3783-3790.
87. Holmes, E.; Loo, R.L.; Stamler, J.; Bictash, M.; Yap, I.K.S.; Chan, Q.; Ebbels, T,; De Iorio, M,; Brown,I.J,; Veselkov, K,A,; Daviglus, M.L,; Kesteloot, H,; Ueshima, H,; Zhao, L,; Nicholson, J.K,; Elliott, P. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature, 2008, 453, 396-401.
88. Kenny, LC.; Broadhurst, D.I.; Dunn, W.B.; Brown, W.; North, R.A.; McCowan, L,; Roberts, C,; Cooper, G.J,; Kell, D.B,; Baker, P.N. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010, 56, 741-749.
89. Kenny, L.C.; Broadhurst, D.; Brown, M.; Dunn, W.B.; Redman, C.W.G.; Kell, D.B,; Baker, P.N. Detection and identification of novel metabolomic biomarkers in preeclampsia. Reprod. Sci., 2008, 15, 591-597.
90. Sabatine, M. S.; Liu, E.; Morrow, D.A.; Heller, E.; McCarroll, R.; Wiegand, R.; Berriz, G. F.; Roth, F.P.; Gerszten, R.E. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation, 2005, 112, 3868-3875.
91. Barba, I.; de León, G.; Martín, A.; Aguade, S.; Candell-Riera, J.; Barrabés, J.A,; Garcia-Dorado, D. Nuclear magnetic resonancebased metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Reson. Med., 2008, 60, 27-32.
92. Turer, A.T.; Stevens, R.D.; Bain, J.R.; Muehlbauer, M.J,; van der Westhuizen, J,; Mathew, J.P,; Schwinn, D.A,; Glower, D.D,; Newgard, C.B,; Podgoreanu, M.V. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation, 2009, 119, 1736-1746.
93. Vallejo, M.; García, A.; Tuñón, J.; García-Martínez, D.; Angulo, S.; Martin-Ventura, J.L.; Blanco-Colio, L.M.; Almeida, P.; Egido, J.; Barbas, C. Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal. Bioanal. Chem., 2009, 394, 1517-1524.
94. ], Z.; Tang, W.H.; Cho, L.; Brennan, D.M.; Hazen, S.L. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 1383-1391.
95. Lewis, G.D.; Wei, RU.; Liu E.; Yang, E,; Shi, X,; Martinovic, M,; Farrell, L,; Asnani, A,; Cyrille, M,; Ramanathan, A,; Shaham, O,; Berriz, G,; Lowry, PA,; Palacios, I.F,; Ta-an, M,; Roth, F.P,; Min. J,; Baumgartner, C,; Keshishian, H,; Addona, T,; Mootha, V.K,; Rosenzweig, A,; Carr, S.A,; Fifer, M.A,; Sabatine, M.S,; Gerszten, RE. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J. Clin. Invest., 2008, 118, 3503-3512.
96. Dunn, W.B.; Broadhurst, D.I.; Deepak, S.M.; Buch, M.H.; McDowell, G.; Spasic, I,; Ellis, D,; Brooks, N,; Kel,l D,; Neyses L. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudoruridine and 2-oxoglutarate. Metabolomics, 2007, 3, 413-426.
97. Samuel, J.L.; Schaub, M. C.; Zaugg, M.; Mamas, M.; Dunn, W.B.; Swynghedauw, B. Genomics in cardiac metabolism. Cardiovasc. Res., 2008, 79, 218-227.
98. Mayr, M.; Yusuf, S.; Weir, G.; Chung, Y.L.; Mayr, U.; Yin, X.; Ladroue, C.; Madhu, B.; Roberts, N.; De Souza, A.; Fredericks, S.; Stubbs, M.; Griffiths, J.R.; Jahangiri, M.; Xu, Q.; Camm, A.J. Combined metabolomic and proteomic analysis of human atrial fibrillation. J. Am. Coll. Cardiol., 2008, 51(5), 585-594.
99. Alexander, D.; Lombardi, R.; Rodriguez, G.; Mitchell, M.M.; Marian, A.J. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur. J. Clin. Invest., 2011, 41(5), 527-538.
100. Li, N. J.; Liu, W. T.; Li, W.; Li, S.Q.; Chen, X.H.; Bi, K.S.; He, P. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem., 2010, 43, 992-997.
101. Greenberg, N.; Grassano, A.; Thambisetty, M.; Lovestone, S.; Legido-Quigley, C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis, 2009, 30, 1235-1239.
102. Sato, Y.; Suzuki, I.; Nakamura, T.; Bernier, F.; Aoshima, K.; Oda, Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res., 2012, 53(3), 567-576.
103. Fonteh, A.N.; Harrington, R.J.; Tsai, A.; Liao, P.; Harrington, M.G. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids, 2007, 32(2), 213-224.
104. Morgan, J. C.; Mehta, S.H.; Sethi, K.D. Biomarkers in Parkinson's Disease. Curr. Neurol.Neurosci. Rep., 2010, 1-8.
105. Quinones, M.P.; Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis., 2009, 35(2), 165-176.
106. Underwood, B.R.; Broadhurst, D.; Dunn, W.B.; Ellis, D.I.; Michell, A.W.; Vacher, C.; Mosedale, D.E.; Kell, D.B.; Barker, R.A.; Grainger, D.J.; Rubinsztein, D.C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain, 2006, 129, 877-886.
107. Paige, L.A.; Mitchell, M.W.; Krishnan, K.R.R.; Kaddurah-Daouk, R.; Steffens, D.C. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry, 2007, 22, 418-423.
108. Zheng, P.; Gao, H.C.; Li Q.; Shao W.H.; Zhang M.L.; Cheng K.; Yang de Y.; Fan S.H.; Chen L.; Fang L.; Xie P. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res., 2012, 11(3), 1741-1748.
109. Kaddurah-Daouk, R.; Yuan, P.; Boyle, S.H.; Matson, W.; Wang, Z.; Zeng, Z.B.; Zhu, H.; Dougherty, G.G.; Yao, J.K.; Chen, G.; Guitart, X.; Carlson, P.J.; Neumeister, A.; Zarate, C.; Krishnan, R.R.; Manji, H.K.; Drevets, W. Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci. Rep. 2012, 2, 667.
110. Ohdoi, C.; Nyhan, W.L.; Kuhara, T. Chemical diagnosis of Lesch-Nyhan syndrome using gas chromatography-mass spectrometry detection. J. Chrom B: Analyt. Technol. Biom. Life Sci., 2003, 792, 123-130.
111. Sinclair, A. J.; Ball, A.K.; Burdon, M.A.; Clarke, C.E.; Stewart, P.M.; Curnow, S.J.; Rauz, S. Exploring the pathogenesis of IIH: An inflammatory perspective. J. Neuroimmunol., 2008, 15, 201-202, 212-220.
112. Sinclair, A.J.; Viant, M.R.; Ball, A.K.; Burdon, M.A.; Walker, E.A.; Stewart, P.M.; Rauz, S.; Young, S.P. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases -A diagnostic tool? NMR Biomed., 2010, 23, 123-132.
113. Tumani, H.; Hartung, H.P.; Hemmer, B.; Teunissen, C.; Deisenhammer, F.; Giovannoni, G.; Zettl, U.K. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis., 2009, 35, 117-127.
114. Pan, Z.; Gu, H.; Talay, N.; Chen, H.; Shanaiah, N.; Hainline, B,E.; Cooks, R.G.; Raftery, D. Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem., 2007, 387, 539-549.
115. Wikoff, W.R.; Gangoiti, J.A.; Barshop, B.A.; Siuzdak, G. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin. Chem., 2007, 53, 2169-2176.
116. Li, X.; Yang, S.; Qiu, Y.; Zhao, T.; Chen, T.; Su, M.; Chu, L.; Lv, A.; Liu, P.; Jia, W. Urinary metabolomics as a potentially novel diagnostic and stratification tool for knee osteoarthritis. Metabolomics, 2010b, 6, 109-118.
117. Zhai, G.; Wan-Sattler, R.; Hart, D.J.; Arden, N.K.; Hakim, A.J- Illig, T.; Spector, T.D. Serum branched-chain amino acid to histidine ratio: A novel metabolomic biomarker of knee osteoarthritis. Ann. Rheum. Dis., 2010, 69, 1227-1231.
118. Bernini, P.; Bertini, I.; Calabrò, A.; la Marca, G.; Lami, G.; Luchinat, C,; Renzi, D,; Tenori, L. Are patients with potential celiac disease really potential? The answer of metabonomics. J. Proteome Res., 2011, 10, 714-721.
119. Bertini, I.; Calabró, A.; De Carli, V.; Luchinat, C.; Nepi, S.; Porfirio, B.; Renzi, D.; Saccenti, E.; Tenori, L. The metabonomic signature of celiac disease. J. Proteome Res., 2009, 8, 170-177.
120. Marchesi, J.R.; Holmes, E.; Khan, F.; Kochhar, S.; Scanlan, P.; Shanahan, F.; Wilson, I.D.; Wang, Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res., 2007, 6, 546-551.
121. Jansson, J.; Willing, B.; Lucio, M.; Fekete, A.; Dicksved, J.; Halfvarson, J.; Tysk, C.; Schmitt-Kopplin, P. Metabolomics reveals metabolic biomarkers of Crohn's disease. Plos One, 2009, 4, 1-10
122. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; O'Donnell, J.; Carr, S.A.; Mootha, V.K.; Florez, J.C.; Souza, A.; Melander, O.; Clish, C.B.; Gerszten, R.E. Metabolite profiles and the risk of developing diabetes. Nat. Med., 2011, 17, 448-454.
123. Lucio, M.; Fedete, A.; Weigert, C.; Wägele, B.; Zhao X.; Chen, J.; Fritsche, A.; Häring HU, Schleicher, E.D.; Xu, G.; Schmitt-Kopplin, P.; Lehmann, R. Insulin sensitivity is reflected by characteristic metabolic fingerprints-A Fourier transform mass spectrometric non-targeted metabolomics approach. Plos One, 2010, 5, 1-9.
124. Zhang, J.; Yan, L.; Chen, W.; Lin, L.; Song, X.; Yan, X.; Hang, W.; Huang, B. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-qTOF-MS system. Anal. Chim. Acta, 2009, 650, 16-22.
125. Yuan, K.; Kong, H.; Guan, Y.; Yang, J.; Xu, G. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci., 2007, 850, 236-240.
126. Suhre, K.; Meisinger, C.; Döring, A.; Altmaier, E.; Belcredi, P.; Gieger, C.; Chang, D.; Milburn, MV.; Gall, WE.; Weinberger, KM.; Mewes, HW.;Hrabé de Angeli,s M.;Wichmann, HE.; Kronenberg, F.; Adamski, J.; Illig, T. Metabolic footprint of diabetes: A multiplatform metabolomics study in an epidemiological setting. Plos One, 2010, 5, 1-11.
127. Li, X.; Xu, Z.; Lu, X.; Yang, X.; Yin, P.; Kong, H.; Yu, Y.; Xu, G. Comprehensive two-dimensional gas chromatography/time-offlight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal. Chim. Acta, 2009, 633(2); 257-262.
128. Gall, W.E.; Beebe K.; Lawton K.A.; Adam K.P.; Mitchell M.W.; Nakhle P.J.; Ryals J.A.; Milburn M.V.; Nannipieri M.; Camastra S.; Natali A.; Ferrannini E.; RISC Study Group. Alphahydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One, 2010, 5(5), e10883.
129. Fukui, Y.; Kato, M.; Inoue, Y.; Matsubara, A.; Itoh, K. A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2009, 877, 3806-3812.
130. Tao, X.; Liu, Y., Wang, Y., Qiu, Y., Lin, J., Zhao, A., Su, M., & Jia, W. GC-MS with ethyl chloroformate derivatization for comprehensive analysis of metabolites in serum and its application to human uremia. Anal. Bioanal. Chem., 2008, 391, 2881-2889.
131. Mirnezami, R.; Kinross, J.M.; Vorkas, P.A.; Goldin, R.; Holmes, E.; Nicholson J.; Darzi A. Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann. Surg. 2012, 255, 5, 881-889.
132. Wei, J.; Xie, G.; Zhou, Z.; Shi, P.; Qiu, Y.; Zheng, X.; Chen,T.; Su, M.; Zhao, A.; Jia W. Salivary metabolite signatures of oral cancer and leukoplakia. Int. J. Cancer, 2011, 129, 2207-2217.
133. Tang, F.;Xie, C.;Huang, D.; Wu, Y.; Zen, M.;Yi, L.; Wang, Y.; Mei, W.; Cao, Y.; Sun, L. Novel potential markers of nasophyringeal carcinoma for diagnosis and therapy. Clin. Biochem., 2011, 44, 711-718.
134. Huang, Z.; Lin, L.; Gao, Y.; Chem, Y.; Yan, X.; Xing, J.; Hang, W. Bladder cancer determination via two urinary metabolites: A biomarker pattern approach. Mol. Cell. Proteomics, 2011, 10, 1-10.
135. Lin, L.; Huang, H.; Gao, Y.; Yan, X.; Xing, J.; Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res., 2011, 10, 1396-1405.
136. Gao, H.; Lu, Q.; Liu, X.; Cong, H.; Zhao, L., Wang, H., Lin, D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci., 2009, 100, 782-785.
137. OuYang, D.; Xu, J.; Huang, H. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl. Biochem. Biotechnol., 2011, 165, 148-154.
138. Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun. Mass Spectrom., 2009, 23, 487-494.
139. Teul, J.; Garcia, A.; Tuñón, J.; Martin-Ventura, J.L.; Tarín, N.; López Bescós, L.; Egido, J.; Barbas, C.; Rúpérez, F.J. Targeted and non-targeted metabolic time trajectory in plasma o patients after acute coronary syndrome. J. Pharm. Biomed. Anal., 2011, 56, 343-351.
140. Lin, H.; Zhang, J.; Gao, P. Silent myocardial ischemia is associated with altered plasma phospholipids. J. Clin. Lab. Anal., 2009, 23, 45-50.
141. Walter, A.; Korth, U.; Hilgert, M.; Hartmann, J.; Weichel, O.; Fassbender, K.; Schmitt, A.; Klein, J. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging, 2004, 25, 1299-1303.
142. Bogdanov, M.; Matson, W.R.; Wang, L.; Matson, T.; Saunders-Pullman, R.; Bressman, S.S.; Beal, M.F. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain, 2008, 131, 389-396.
143. Dunckley, T.; Coon, K.D.; Stephan, D.A. Discovery and development of biomarkers of neurological disease. Drug Discov. Today, 2005, 10, 326-334.
144. Ooi, M.; Nishiumi, S.; Yoshie, T.; Shiomi, Y.; Kohashi, M.; Fukunaga, K.; Nakamura, S.; Matsumoto, T.; Hatano, N.; Shinohara, M.; Irino, Y.; Takenawa, T.; Azuma, T.; Yoshida, M. GC/MSbased profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm. Res., 2011, 60, 831-840.